New Zealand Prime Minister Jacinda Ardern receiving her first Pfizer/BioNTech dose, June 18 (Alex Burton/NZ Herald via AP Images)

Covid-19 roundup: Af­ter win­ning an EUA, GSK and Vir are back with full da­ta on their mon­o­clon­al an­ti­body; New Zealand au­tho­rizes Pfiz­er/BioN­Tech vac­cine for kids as young as 12

A few weeks af­ter snag­ging an emer­gency use au­tho­riza­tion for their mon­o­clon­al an­ti­body sotro­vimab based on in­ter­im da­ta, GSK and Vir Biotech­nol­o­gy are back with con­fir­ma­to­ry re­sults to sup­port the drug’s use in non-hos­pi­tal­ized Covid-19 pa­tients.

Sotro­vimab re­duced hos­pi­tal­iza­tion of more than 24 hours or death by 79% at Day 29 com­pared to place­bo, the part­ners said on Mon­day. The pri­ma­ry analy­sis was based on 1,057 pa­tients with mild to mod­er­ate Covid-19.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA